August 27, 2019

Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million

GALVESTON, Texas, Aug. 27, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as

Read More »